Citius Oncology, Inc. (CTOR)
CTOR moved a median of 0.00% 30 minutes after news, and -0.89% by the close. How CTOR actually reacts to news — the realized, point-in-time move the market made, measured across 176 labeled events over the last three years with zero look-ahead.
CTOR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 161 |
| 30-min | 0.00% | 50% | 173 |
| 60-min | -1.16% | 28% | 176 |
| to close | -0.89% | 38% | 174 |
| Middle 50% of CTOR reactions | -2.40% to +1.67% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 176 |
Half of all Citius Oncology, Inc. news events land between -2.40% and +1.67% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CTOR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CTOR's baseline. Nothing else.
Recent CTOR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K CITIUS ONCOLOGY, INC. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.34% | |
| Form ARS CITIUS ONCOLOGY, INC. For: Sep 30 | SEC filing · Form ARS | SEC EDGAR | — | -1.61% | |
| Form DEF 14A CITIUS ONCOLOGY, INC. For: Sep 29 | SEC filing · Form DEF | SEC EDGAR | — | -1.61% | |
| Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | -2.55% | -4.12% | |
| Form 10-Q CITIUS ONCOLOGY, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.55% | -4.12% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -2.55% | -4.12% | |
| Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri | Press release | PR Newswire | -5.71% | +8.20% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -5.71% | +8.20% | |
| Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment | Press release | PR Newswire | +4.63% | +20.81% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +4.63% | +20.81% | |
| Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption | Press release | PR Newswire | +4.61% | -3.04% | |
| Form EFFECT CITIUS ONCOLOGY, INC. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +3.88% | |
| Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies | Press release | PR Newswire | +0.00% | -0.84% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.24% | |
| Form DEF 14C CITIUS ONCOLOGY, INC. For: May 29 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -0.84% | |
| Form S-3 CITIUS ONCOLOGY, INC. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -0.84% | |
| Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting | Press release | PR Newswire | — | +3.61% | |
| Form PRE 14C CITIUS ONCOLOGY, INC. For: May 19 | SEC filing · Form PRE | SEC EDGAR | +1.50% | +3.25% | |
| Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | -4.50% | -5.27% | |
| Form 10-Q CITIUS ONCOLOGY, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.50% | -5.27% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -4.50% | -5.27% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | — | -4.06% | |
| Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization | Press release | PR Newswire | — | -4.06% | |
| Citius Oncology Ships First International Order of LYMPHIR™ to Europe | Press release | PR Newswire | +0.00% | -4.44% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -0.57% | +1.73% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.44% | |
| Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development | Press release | PR Newswire | -4.82% | +13.12% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -7.85% | +1.34% | |
| Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts | Press release | PR Newswire | -6.05% | -11.71% | |
| Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers | Press release | PR Newswire | -2.00% | +0.50% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | +0.50% | |
| Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma | Press release | PR Newswire | -0.93% | +0.93% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | -0.93% | +0.93% | |
| Form EFFECT CITIUS ONCOLOGY, INC. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -0.94% | |
| Form POS AM CITIUS ONCOLOGY, INC. | SEC filing · Form POS | SEC EDGAR | -2.15% | -1.72% | |
| Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ | Press release | PR Newswire | -1.88% | +1.67% | |
| Form 10-Q CITIUS ONCOLOGY, INC. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.88% | +1.67% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Feb 13 | SEC filing · Form 8-K | SEC EDGAR | -1.88% | +1.67% | |
| Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar | Press release | PR Newswire | -0.59% | +0.89% | |
| Form DEF 14C CITIUS ONCOLOGY, INC. For: Jan 29 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -1.85% | |
| Form PRE 14C CITIUS ONCOLOGY, INC. For: Jan 20 | SEC filing · Form PRE | SEC EDGAR | +0.96% | +10.58% | |
| Form EFFECT CITIUS ONCOLOGY, INC. | SEC filing · Form EFFECT | SEC EDGAR | +2.83% | +2.83% | |
| Form S-3 CITIUS ONCOLOGY, INC. | SEC filing · Form S-3 | SEC EDGAR | -6.09% | +4.35% | |
| Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update | Press release | PR Newswire | +4.07% | -6.91% | |
| Form 10-K CITIUS ONCOLOGY, INC. For: Sep 30 | SEC filing · Form 10-K | SEC EDGAR | +4.07% | -6.91% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +4.07% | -6.91% | |
| Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | +0.89% | +0.89% | |
| Form 8-K CITIUS ONCOLOGY, INC. For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | +0.89% | |
| Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | +0.97% | +13.72% | |
| Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim | Press release | PR Newswire | +1.72% | -4.31% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CTOR section they belong to.
Where else CTOR is measured.
CTOR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Citius Oncology, Inc.'s median reaction calculated?
Every labeled CTOR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 176 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of CTOR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CTOR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.